HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.

HPS2-THRIVE Collaborative Group; Jiang, L; Hopewell, J; Collins, R; Armitage, J

Journal article

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.

Abstract:: AimsNiacin has potentially favourable effects on lipids, but its effect on cardiovascular outcomes is uncertain. HPS2-THRIVE is a large randomized trial assessing the effects of extended release (ER) niacin in patients at high risk of vascular events.

Methods and results Prior to randomization, 42 424 patients with occlusive arterial disease were given simvastatin 40 mg plus, if required, ezetimibe 10 mg daily to standardize their low-density lipopro...
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Group, H. P. S.-T. H. R. I. V. E. C., Jiang, L., Hopewell, J., Collins, R., & Armitage, J. (2013). HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal, 34(17), 1279–1291.

MLA Style

Group, H. PS2-T. HR IV E. Collaborative, et al. “HPS2-THRIVE Randomized Placebo-Controlled Trial in 25 673 High-Risk Patients of ER Niacin/Laropiprant: Trial Design, Pre-Specified Muscle and Liver Outcomes, and Reasons for Stopping Study Treatment.” European Heart Journal, vol. 34, no. 17, Oxford University Press, 2013, pp. 1279–91.

Chicago Style

Group, HPS2-THRIVE Collaborative, L Jiang, J Hopewell, R Collins, and J Armitage. 2013. “HPS2-THRIVE Randomized Placebo-Controlled Trial in 25 673 High-Risk Patients of ER Niacin/Laropiprant: Trial Design, Pre-Specified Muscle and Liver Outcomes, and Reasons for Stopping Study Treatment.” European Heart Journal 34 (17): 1279–91.
Tweet
Print

Access Document

Files:: Eur Heart J-2013--1279-91.pdf

(Preview, Version of record, pdf, 326.9KB, Terms of use)

Publisher copy:: 10.1093/eurheartj/eht055

Authors

+ HPS2-THRIVE Collaborative Group More by this author

Role:

Author

+ Jiang, L More by this author

Institution:

University of Oxford

Division:

MSD

Department:

Nuffield Department of Population Health

Sub department:

Clinical Trial Service Unit

Role:

Author

+ Hopewell, J More by this author

Institution:

University of Oxford

Division:

MSD

Department:

RDM

Sub department:

RDM Cardiovascular Medicine

Role:

Author

+ Collins, R More by this author

Institution:

University of Oxford

Division:

MSD

Department:

Nuffield Department of Population Health

Sub department:

Clinical Trial Service Unit

Role:

Author

+ Armitage, J More by this author

Institution:

University of Oxford

Division:

MSD

Department:

Nuffield Department of Population Health

Sub department:

Clinical Trial Service Unit

Role:

Author

Funding

+ British Heart Foundation More from this funder

Funding agency for:

Hopewell, J

Grant:

RE/08/004

+ Cancer Research UK More from this funder

+ Merck More from this funder

+ Medical Research Council More from this funder

Bibliographic Details

Publisher:: Oxford University Press
Journal:: European heart journal More from this journal
Volume:: 34
Issue:: 17
Pages:: 1279-1291
Publication date:: 2013-05-01
DOI:: 10.1093/eurheartj/eht055
EISSN:: 1522-9645
ISSN:: 0195-668X

Item Description

Language:: English
Keywords:: Myocardial Reperfusion

Drug Therapy, Combination

Female

Niacin

Delayed-Action Preparations

HPS2-THRIVE Collaborative Group

Arterial Occlusive Diseases

Simvastatin

Male

Drug-Induced Liver Injury

Indoles

Hypolipidemic Agents

Myocardial Infarction

Death, Sudden, Cardiac

Stroke

Muscular Diseases

Middle Aged

Humans
UUID:: uuid:66709c95-09e8-43b8-ad3d-76c78a1cdc9c
Local pid:: pubs:403066
Source identifiers:: 403066
Deposit date:: 2013-11-16

Terms of use

Copyright holder:: HPS2-THRIVE Collaborative Group
Notes:: Copyright © 2013 HPS2-THRIVE Collaborative Group. Published by Oxford University Press on behalf of European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial reuse, distribution, and reproduction in any medium, provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oup.com.

Licence:: CC Attribution-NonCommercial (CC BY-NC)

Metrics

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

Journal article

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.

Actions

Access Document

Authors

Funding

Bibliographic Details

Item Description

Terms of use

Metrics

Views and Downloads

Altmetrics

Dimensions